QUESTALPHA GmbH & Co. KG and Tissue-Link: A partnership for treatment of severe surgical and traumatic bleeding
Eschenburg, July 10, 2025 - QUESTALPHA GmbH & Co. KG, a leading medical technology company, and Tissue-Link ApS, a pioneer in the development of advanced medical products, are pleased to announce their development collaboration. Together, they are committed to developing innovative hemostatic dressing solutions, aimed at saving the lives of patients.
Joint efforts for improved patient care
This partnership combines the strengths and commitment of both companies to develop advanced hemostatic dressings providing a strong, sustaining, and topical clot formation securing hemostasis efficiently. These wound care products are specifically designed for use in emergency situations and surgical procedures and are intended to significantly improve patient outcome.
New technology and platform technology
Tissue-Link has developed a breakthrough invention in the field of protein coupling which has led to the creation of a unique, patented technology. This concept enables safe use of highly potent biomolecules and has far-reaching applications in the field of human health. The first product from this technology is a revolutionary hemostatic medical device for the treatment of severe bleeding.
Quotes
"At QUESTALPHA, we follow a patient-oriented approach. Our mission is to improve the lives of patients through innovative solutions. The collaboration with Tissue-Link is a significant step in this direction. Together we combine our innovative strengths and develop groundbreaking products that represent a significant improvement of current treatment option Our active hemostat represents a significant improvement of current treatment options." says Dr. Sebastian Breuer, Managing Director of QUESTALPHA GmbH & Co. KG.
“At Tissue-link we aim to improve patient health by use of our breakthrough technology. Our partnership with QUESTALPHA will play a key role in bringing our first active hemostat to market and this is the perfect way to move fast forward with a solution for improved patient health in patients suffering from severe bleedings, including artery lesions, says Dr. Charlotte Videbaek, Chairman of the board of Tissue-Link ApS. "This partnership marks a major step toward creating truly innovative and life-saving solutions.”
About QUESTALPHA GmbH & Co. KG
QUESTALPHA GmbH & Co. KG is a leading medical technology company specializing in the development and manufacture of innovative products for diagnostics, wound care and further applications. With a strong focus on research and development, the company sets new standards in the industry. QUESTALPHA does not only rely on its extensive experience with medical grade sponge material, but also find further innovative solutions based on other materials to provide the solid phase for the customers that exactly solves their challenges.
About Tissue-Link
Tissue-Link ApS is an innovative biotechnology company based in the Greater Copenhagen area, Denmark. The company was created to address critical challenges in controlling severe bleeding through advanced hemostatic products. Tissue-Link has made significant progress in developing proprietary technology that leverages natural human proteins, to enhance efficacy and safety, particularly in severe acute and surgical settings.
Contact
For further information please contact:
QUESTALPHA GmbH & Co. KG
Im Heerfeld 7
35713 Eschenburg
02774-705-505
info@questalpha.com
Tissue-Link ApS
Harhoffs Alle 38
4100 Ringsted
info@tissue-link.com